Five Prime Therapeutics

FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cally rel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity, and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap, and Advanced Tech­nol­ogy Ventures.

This tiny biotech might be developing a major new cancer drug.

Why Five Prime Therapeutics Stock Gained 312% in November

Cardiff Oncology

Mersana Therapeutics

Surface Oncology Inc

Trillium Therapeutics

Biotech investors had more than just vaccines to think about this year.

These Were the 5 Best Cancer Stocks Of 2020

West Pharmaceutical Services

Fulgent Genetics

There are plenty of healthcare stocks that have seen share growth this year. Here are three lesser-known stocks that have the potential to continue that growth this month and beyond.

Have $1,000? Here Are 3 Top Healthcare Stocks to Buy in December

Five Prime Therapeutics declared outstanding results last month and went up nearly 400%. Given the market potential, there may still be considerable upside.

Five Prime Therapeutics: Primed For Growth

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Announces Closing of Upsized Public Offering of Common Stock

Five Prime Announces Closing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (Nasdaq: FPRX), announced today the pricing of an underwritten public offering of 7,200,000 shares of its common stock at a price to the public of $21.00 per share. The size of the offering was upsized from 5,000,000 shares to 7,200,000 shares. Five Prime estimates that the net proceeds from the sale of the shares will be approximately $141.9 million, after deducting underwriting discounts and commissions and estimated

Five Prime Announces Pricing of Upsized Public Offering of Common Stock

Five Prime Therapeutics stock popped for a second day running Thursday after the small biotech company unveiled promising preclinical data for an experimental cancer treatment. The post Small Biotech Five Prime Launches For A Second Day Running — Here's Why appeared first on Investor's Business Daily.

Small Biotech Five Prime Launches For A Second Day Running — Here's Why

Investors need to pay close attention to Five Prime (FPRX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Five Prime (FPRX) Stock?

The stock price of Five Prime Therapeutics Inc (NASDAQ: FPRX) has increased by 237.08% on Wednesday. These are the details.

FPRX Stock Price: Explanation About The 237.08% Increase

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Announces Proposed Public Offering of Common Stock

Five Prime Announces Proposed Public Offering of Common Stock

And as a bonus, find out which much-loved stock let its shareholders down.

You've Probably Never Heard of the Stock Market's Biggest Winner Wednesday

Shares of FPRX stock are skyrocketing on Wednesday after the company reported positive results from its stomach cancer treatment trial. The post Five Prime Therapeutics: 6 Things for FPRX Stock Investors to Know Now appeared first on InvestorPlace.

Five Prime Therapeutics: 6 Things for FPRX Stock Investors to Know Now

Can-Fite BioPharma Ltd.

GT Biopharma Inc

InflaRx

Tonix Pharmaceuticals Hld

vTv Therapeutics

Vaxart

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech Penny Stocks Worth a Gamble appeared first on InvestorPlace.

7 Biotech Penny Stocks Worth a Gamble

Five Prime Therapeutics Inc. (NASDAQ: FPRX) shares more than tripled on Wednesday after the company announced positive topline results from its gastric cancer study.

Why Five Prime Therapeutics Stock Skyrocketed on Wednesday

Shares of Five Prime Therapeutics skyrocketed early Wednesday after the tiny biotech stock's stomach cancer treatment, a drug known as bemarituzumab, passed muster in a midstage test. The post Why This Tiny Biotech Stock Just Skyrocketed 285% In Bullish Volume appeared first on Investor's Business Daily.

Why This Tiny Biotech Stock Just Skyrocketed 285% In Bullish Volume

Five Prime Therapeutics Inc (NASDAQ: FPRX) shares are seeing astronomical gains Wednesday in reaction to a positive data readout. What Happened: Bemarituzumab, a targeted therapy, in combination with FOLFOX6 chemotherapy, met all three efficacy endpoints in the Phase 2 study dubbed FIGHT in patients with fibroblast growth factor receptor 2b-positive, non HER2 positive, front-line advanced gastric or gastroesophageal junction cancer, the South San Francisco, California-based company said, citing topline results.

Five Prime's Stock Quadruples On Positive Mid-Stage Stomach Cancer Study

A potential breakthrough in the treatment of stomach cancer helped boost shares of Five Prime Therapeutics higher by as much as 386% to $26.00 in Tuesday pre-market trades. The small-cap biotechnology company said on Monday that its phase 2 FIGHT trial evaluating bemarituzumab in front-line advanced gastric cancer and gastroesophageal junction cancer met all 3 pre-determined efficacy endpoints.

Five Prime Therapeutics soars 386% after positive cancer trial results (FPRX)

The biotech's stomach cancer drug hit the mark in a midstage trial.

Why Five Prime Therapeutics Stock Is on Fire Today

Shares of Five Prime Therapeutics Inc. blasted 353% higher on heavy volume toward a three-year high in premarket trading Wednesday, after the company said its treatment for gastric cancer met all three of its efficacy endpoints from Phase 2 trial. Trading volume ballooned to 2.9 million shares, compared with the full-day average of about 659,000 shares.

Five Prime's stock rockets over 350% after positive trial results from cancer treatment, analyst upgrade

Shares of Five Prime Therapeutics Inc. blasted 314% higher in premarket trading Wednesday, after the company said its treatment for gastric cancer met all three of its efficacy endpoints from Phase 2 trial. The rally put the stock on track to open at the highest level seen during regular-session hours since February 2018.

Five Prime's stock rockets fourfold after positive trial results from cancer treatment, analyst upgrade

Five Prime Therapeutics, Inc. (FPRX) CEO Tom Civik on Q3 2020 Results - Earnings Call Transcript

Five Prime Therapeutics, Inc. (FPRX) CEO Tom Civik on Q3 2020 Results - Quick Version Earnings Call Transcript

Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Five Prime Therapeutics (FPRX) Reports Q3 Loss, Lags Revenue Estimates

Shares of Five Prime Therapeutics (NASDAQ:FPRX) were unchanged in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 28.16% over the past year to ($0.74), which missed the estimate of ($0.60).

Recap: Five Prime Therapeutics Q3 Earnings

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics Reports Third Quarter 2020 Results

News for Five Prime Therapeutics Stock (FPRX)